Pubblicazioni
1. | Local Recurrence and Survival in Patients With Melanoma >2 mm in Thickness at Difficult Sites Treated With 1-cm Versus 2-cm Margins. Maurichi A, Barretta F, Patuzzo R, Gallino G, Mattavelli I, Shimonovitz-Moore M, Nizri E, Matteucci M, Summo V, Cossa M, Valeri B, Cortinovis U, Miceli R, Santinami M. J Natl Compr Canc Netw. 2024 Nov 13;22(10):687-693. doi: 10.6004/jnccn.2024.7040. PMID: 39536446 |
2. | A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors. Medri M, Savoia F, Foca F, Miserocchi A, Quaglino P, Rubatto M, Gullo G, Nardini C, Panasiti V, DE Tursi M, DI Marino P, Brancaccio G, Giunta EF, Napolitano S, Cinotti E, Brusasco M, Stanganelli I; IMI, Italian Melanoma Intergroup. Ital J Dermatol Venerol. 2023 Dec;158(6):437-444. doi: 10.23736/S2784-8671.23.07542-4. PMID: 38015482 |
3. | Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study. Mattavelli I, Patuzzo R, Galeone C, Pelucchi C, Gallino G, Leva A, Valeri B, Santinami M, Maurichi A. Melanoma Res. 2023 Aug 1;33(4):309-315. doi: 10.1097/CMR.0000000000000898. Epub 2023 May 5. PMID: 37162530 |
4. | The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup. Patuzzo R, Mattavelli I, Gallino G, Galeone C, Valeri B, Mocellin S, Del Fiore P, Ribero S, Mandalà M, Tauceri F, Lombardo M, Maurichi A; Italian Melanoma Intergroup. Cancer. 2023 Aug 1;129(15):2331-2340. doi: 10.1002/cncr.34824. Epub 2023 May 10. PMID: 37162404 |
5. | European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma. Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalhal S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglino P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P, Sersa G, Valpione S; Melanoma Delphi Working Group. Br J Surg. 2023 Jun 12;110(7):818-830. doi: 10.1093/bjs/znad105. PMID: 37131298 |
6. | Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures. Maurichi A, Barretta F, Patuzzo R, Sala L, Miceli R, Gallino G, Mattavelli I, Leva A, Simonotti N, Taglione B, Cossa M, Belotti A, Valeri B, Cortinovis U, Santinami M. JAMA Dermatol. 2023 Jun 1;159(6):587-595. doi: 10.1001/jamadermatol.2023.0620. PMID: 37043209 Free PMC article. |
7. | Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study. Maurichi A, Barretta F, Patuzzo R, Miceli R, Gallino G, Mattavelli I, Leva A, Harwood C, Bergamaschi D, Borg TM, Shimonovitz-Moore M, Spadola G, Tolomio E, Barbieri C, Queirolo P, Manganoni AM, Pellacani G, Espeli V, Mangas C, Leoni-Parvex S, Cossa M, Belotti A, Valeri B, Cortinovis U, Santinami M. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1318-1326. doi: 10.1111/jdv.19051. Epub 2023 Mar 27. PMID: 36924058 |
8. | The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086). Tropea S, Del Fiore P, Maurichi A, Patuzzo R, Santinami M, Ribero S, Quaglino P, Caliendo V, Borgognoni L, Sestini S, Giudice G, Nacchiero E, Caracò C, Cordova A, Solari N, Piazzalunga D, Tauceri F, Carcoforo P, Lombardo M, Cavallari S, Mocellin S; Italian Melanoma Intergroup (IMI). BMC Cancer. 2022 Jun 3;22(1):610. doi: 10.1186/s12885-022-09705-y. PMID: 35659273 Free PMC article. |
9. | The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. Stanganelli I, Spagnolo F, Argenziano G, Ascierto PA, Bassetto F, Bossi P, Donato V, Massi D, Massone C, Patuzzo R, Pellacani G, Quaglino P, Queirolo P, Zalaudek I, Palmieri G, On Behalf Of Italian Melanoma Intergroup Imi. Cancers (Basel). 2022 Jan 13;14(2):377. doi: 10.3390/cancers14020377. PMID: 35053539 Free PMC article. Review. |
10. | Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. PMID: 34355463 Free PMC article. |
11. | Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension. Maurichi A, Barretta F, Patuzzo R, Miceli R, Gallino G, Mattavelli I, Barbieri C, Leva A, Angi M, Lanza FB, Spadola G, Cossa M, Nesa F, Cortinovis U, Sala L, Di Guardo L, Cimminiello C, Del Vecchio M, Valeri B, Santinami M. J Natl Compr Canc Netw. 2021 Jul 26;19(10):1165-1173. doi: 10.6004/jnccn.2020.7693. PMID: 34311443 |
12. | Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). Vanni I, Casula M, Pastorino L, Manca A, Dalmasso B, Andreotti V, Pisano M, Colombino M; Italian Association for Cancer Research (AIRC) Study Group; Pfeffer U, Tanda ET, Rozzo C, Paliogiannis P, Cossu A, Ghiorzo P, Palmieri G; Italian Melanoma Intergroup (IMI). Diagn Pathol. 2020 Dec 14;15(1):143. doi: 10.1186/s13000-020-01052-5. PMID: 33317587 Free PMC article. |
13. | The role of sentinel lymph node status performed in melanoma patients with local recurrence or in transit metastasis. Mattavelli I, Maurichi A, Galeone C, Gallino G, Barbieri C, Leva A, Tolomio E, Valeri B, Cossa M, Patuzzo R, Santinami M. Eur J Surg Oncol. 2021 May;47(5):1152-1156. doi: 10.1016/j.ejso.2020.10.028. Epub 2020 Nov 1. PMID: 33218700 |
14. | Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors. Maurichi A, Miceli R, Patuzzo R, Barretta F, Gallino G, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Tolomio E, Sant M, Castelli G, Zichichi L, Pellacani G, Stanganelli I, Simonacci M, Manganoni A, Del Forno C, Caresana G, Harwood C, Bergamaschi D, Lasithiotakis K, Bennett D, Espeli V, Mangas C, Leoni Parvex S, Valeri B, Cossa M, Barisella M, Pellegrinelli A, Miranda C, Anichini A, Mortarini R, Zoras O, Santinami M. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1327-1336. doi: 10.6004/jnccn.2020.7582. Print 2020 Oct. PMID: 33022642 |
15. | Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30-39]. Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Eur J Cancer. 2020 Nov;139:204-205. doi: 10.1016/j.ejca.2020.09.002. Epub 2020 Sep 23. PMID: 32980191 Free PMC article. No abstract available. |
16. | Surgical treatment of melanoma metastases to the small bowel: A single cancer referral center real-life experience. Gallino G, Maurichi A, Patuzzo R, Mattavelli I, Barbieri C, Leva A, Valeri B, Cossa M, Galeone C, Pelucchi C, Santinami M. Eur J Surg Oncol. 2021 Feb;47(2):409-415. doi: 10.1016/j.ejso.2020.08.025. Epub 2020 Aug 29. PMID: 32917431 |
17. | Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Eur J Cancer. 2020 Sep;137:30-39. doi: 10.1016/j.ejca.2020.07.001. Epub 2020 Jul 30. PMID: 32739767 Free PMC article. |
18. | Reply to E. Hindié. Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23. PMID: 32701413 Free PMC article. No abstract available. |
19. | Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Maurichi A, Miceli R, Eriksson H, Newton-Bishop J, Nsengimana J, Chan M, Hayes AJ, Heelan K, Adams D, Patuzzo R, Barretta F, Gallino G, Harwood C, Bergamaschi D, Bennett D, Lasithiotakis K, Ghiorzo P, Dalmasso B, Manganoni A, Consoli F, Mattavelli I, Barbieri C, Leva A, Cortinovis U, Espeli V, Mangas C, Quaglino P, Ribero S, Broganelli P, Pellacani G, Longo C, Del Forno C, Borgognoni L, Sestini S, Pimpinelli N, Fortunato S, Chiarugi A, Nardini P, Morittu E, Florita A, Cossa M, Valeri B, Milione M, Pruneri G, Zoras O, Anichini A, Mortarini R, Santinami M. J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13. PMID: 32167862 Free PMC article. |
20. | Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment. Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C. J Transl Med. 2019 Sep 18;17(1):315. doi: 10.1186/s12967-019-2067-0. PMID: 31533733 Free PMC article. |
21. | New paradigm for stage III melanoma: from surgery to adjuvant treatment. Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C. J Transl Med. 2019 Aug 14;17(1):266. doi: 10.1186/s12967-019-2012-2. PMID: 31412885 Free PMC article. Review. |
22. | Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, De Laurentiis A, Lalli L, Di Guardo L, Patuzzo R, Vergani B, Casiraghi E, Cossa M, Gualeni A, Bollati V, Arienti F, De Braud F, Mariani L, Villa A, Altevogt P, Umansky V, Rodolfo M, Rivoltini L. J Clin Invest. 2018 Dec 3;128(12):5505-5516. doi: 10.1172/JCI98060. Epub 2018 Nov 5. PMID: 30260323 Free PMC article. |
23. | Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells. Tuccitto A, Tazzari M, Beretta V, Rini F, Miranda C, Greco A, Santinami M, Patuzzo R, Vergani B, Villa A, Manenti G, Cleris L, Giardiello D, Alison M, Rivoltini L, Castelli C, Perego M. Stem Cells. 2016 Oct;34(10):2449-2460. doi: 10.1002/stem.2413. Epub 2016 Jun 28. PMID: 27301067 |
24. | Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M. Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14. PMID: 25971540 Free PMC article. Clinical Trial. |
25. | Electrochemotherapy: a good idea in recurrent basal cell carcinoma treatment. Ruggeri R, Maurichi A, Tinti MC, Cadenelli P, Patuzzo R, Gallino G, Santinami M. Melanoma Manag. 2015 Feb;2(1):27-31. doi: 10.2217/mmt.14.28. Epub 2015 Feb 25. PMID: 30190828 Free PMC article. |
26. | Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. Sandro P, Andrea M, Nicola M, Simone M, Giuseppe M, Lorenzo B, Nicola S, Dario P, Luigi M, Giuseppe G, Roberto P, Corrado C, Simone R, Ugo M, Mario S, Riccardo RC. Ann Surg Oncol. 2015 Jul;22(7):2127-34. doi: 10.1245/s10434-014-4132-5. Epub 2014 Oct 15. PMID: 25316489 |
27. | Armed antibodies for cancer treatment: a promising tool in a changing era. Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M. Cancer Immunol Immunother. 2015 Jan;64(1):113-21. doi: 10.1007/s00262-014-1621-0. Epub 2014 Oct 15. PMID: 25314912 Free PMC article. Review. |
28. | Prediction of survival in patients with thin melanoma: results from a multi-institution study. Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M. J Clin Oncol. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340. Epub 2014 Jul 7. PMID: 25002727 |
29. | Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma. Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M. JAMA Surg. 2014 Jul;149(7):700-6. doi: 10.1001/jamasurg.2013.5676. PMID: 24804856 |
30. | Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M, Rossi CR. J Clin Oncol. 2014 Mar 20;32(9):935-41. doi: 10.1200/JCO.2013.50.7681. Epub 2014 Feb 10. PMID: 24516022 |
31. | Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M. Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672. PMID: 24395820 |
32. | Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. Patuzzo R, Maurichi A, Camerini T, Gallino G, Ruggeri R, Baffa G, Mattavelli I, Tinti MC, Crippa F, Moglia D, Tolomio E, Maccauro M, Santinami M. J Surg Res. 2014 Apr;187(2):518-24. doi: 10.1016/j.jss.2013.10.037. Epub 2013 Oct 23. PMID: 24252855 |
33. | Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C. Cancer Immunol Immunother. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16. PMID: 23589107 Free PMC article. Clinical Trial. |
34. | Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M. Int J Cancer. 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13. PMID: 23151995 |
35. | The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. Ruggeri R, Camerini T, Patuzzo R, Maurichi A, Pirovano R, Mattavelli I, Crippa F, Tolomio E, Moglia D, Di Florio A, Santinami M. Int J Surg Case Rep. 2013;4(1):40-3. doi: 10.1016/j.ijscr.2012.08.013. Epub 2012 Sep 27. PMID: 23108169 Free PMC article. |
36. | Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L. Clin Cancer Res. 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2. PMID: 23032742 Clinical Trial. |
37. | Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, González-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F. J Surg Oncol. 2013 Feb;107(2):173-9. doi: 10.1002/jso.23168. Epub 2012 Jun 4. PMID: 22674435 Clinical Trial. |
38. | Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior. Maurichi A, Miceli R, Camerini T, Contiero P, Patuzzo R, Tragni G, Crippa F, Romanidis K, Ruggeri R, Carbone A, Santinami M. Ann Surg. 2010 Dec;252(6):1052-7. doi: 10.1097/SLA.0b013e3181efc23c. PMID: 21107116 |
39. | Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R. Cancer Res. 2010 Nov 1;70(21):8378-87. doi: 10.1158/0008-5472.CAN-10-2028. Epub 2010 Sep 21. PMID: 20861189 |
40. | Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C. J Invest Dermatol. 2010 Jul;130(7):1877-86. doi: 10.1038/jid.2010.69. Epub 2010 Apr 8. PMID: 20376064 |
41. | Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone. Bajetta E, Celio L, Platania M, Lo Vullo S, Patuzzo R, Maurichi A, Santinami M. Ann Surg Oncol. 2009 Nov;16(11):2985-93. doi: 10.1245/s10434-009-0615-1. Epub 2009 Jul 16. PMID: 19609619 Clinical Trial. |
42. | Multipeptide vaccination in cancer patients. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G. Expert Opin Biol Ther. 2009 Aug;9(8):1043-55. doi: 10.1517/14712590903085109. PMID: 19591629 Review. |
43. | Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A. Clin Cancer Res. 2009 Jun 15;15(12):4085-94. doi: 10.1158/1078-0432.CCR-08-3323. Epub 2009 Jun 9. PMID: 19509154 |
44. | Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. Santinami M, Carbone A, Crippa F, Maurichi A, Pellitteri C, Ruggeri R, Zoras O, Patuzzo R. Melanoma Res. 2009 Apr;19(2):112-8. doi: 10.1097/CMR.0b013e328329fe7d. PMID: 19282788 |
45. | Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Iero M, Filipazzi P, Castelli C, Belli F, Valdagni R, Parmiani G, Patuzzo R, Santinami M, Rivoltini L. Cancer Immunol Immunother. 2009 Jul;58(7):1159-67. doi: 10.1007/s00262-008-0610-6. Epub 2008 Nov 8. PMID: 18998128 Free PMC article. |
46. | Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M. Int J Cancer. 2007 Jun 1;120(11):2439-44. doi: 10.1002/ijc.22598. PMID: 17315191 |
47. | Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, Lenisa L, Mascheroni L, Maurichi A, Pennacchioli E, Patuzzo R, Santinami M, Tragni G. J Clin Oncol. 2006 Sep 20;24(27):4464-71. doi: 10.1200/JCO.2006.06.3198. PMID: 16983115 |
48. | Vaccination: role in metastatic melanoma. Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, Parmiani G, Rivoltini L. Expert Rev Anticancer Ther. 2006 Aug;6(8):1305-18. doi: 10.1586/14737140.6.8.1305. PMID: 16925496 Review. |
49. | Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D’Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L. Cancer Res. 2006 May 1;66(9):4943-51. doi: 10.1158/0008-5472.CAN-05-3396. PMID: 16651452 Clinical Trial. |
50. | A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G. Cancer Immunol Immunother. 2006 Aug;55(8):958-68. doi: 10.1007/s00262-005-0084-8. Epub 2005 Oct 8. PMID: 16215718 Free PMC article. Clinical Trial. |
51. | Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi E, Pennacchioli E, Patuzzo R, Santinami M, Anichini A. Cancer Res. 2005 Apr 15;65(8):3428-36. doi: 10.1158/0008-5472.CAN-04-3239. PMID: 15833878 |
52. | Heat shock proteins and their use as anticancer vaccines. Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M. Clin Cancer Res. 2004 Dec 15;10(24):8142-6. doi: 10.1158/1078-0432.CCR-04-1194. PMID: 15623587 Review. No abstract available. |
53. | Pigmented spindle-cell nevus: a melanoma simulator. Maurichi A, Baldi M, Bartoli C, Bono A, Camerini T, Moglia D, Patuzzo R, Pennacchioli E, Tragni G, Santinami M. Dermatol Online J. 2004 Oct 15;10(2):5. PMID: 15530295 No abstract available. |
54. | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Guadagni S, Santinami M, Patuzzo R, Pilati PL, Miotto D, Deraco M, Rossi CR, Fiorentini G, Di Filippo F, Valenti M, Amicucci G. Melanoma Res. 2003 Feb;13(1):51-8. doi: 10.1097/00008390-200302000-00009. PMID: 12569285 Clinical Trial. |